|
Male gender, n (%)
|
518 (54.5)
|
25 (71.4)
|
0.048
|
2.852 [1.162–6.999]
|
0.022
|
2.738 [1.109–6.762]
|
0.029
|
|
Age, years, median [IQR]
|
67 [59–73]
|
69 [64–74]
|
0.045
| | | | |
|
BMI, kg/m2, median [IQR]
|
26 [24–28.4]
|
25.4 [23.4–28]
|
0.17
| | | | |
|
Presence of diabetes, n (%)
|
121 (12.8)
|
10 (28.6)
|
0.007
|
0.392 [0.155–0.988]
|
0.047
|
0.369 [0.146–0.931]
|
0.047
|
|
Presence of cirrhosis, n (%)
|
696 (73.4)
|
35 (100)
|
0.002
|
0.153 [0.019–1.239]
|
0.079
| | |
|
CTP B classa n (%)
|
72/696 (10.3)
|
10/34 (29.4)
|
0.001
| | |
0.430 [0.170–1.086]
|
0.074
|
|
HCV genotype 1, n (%)
|
724 (77.3)
|
29 (82.9)
|
0.44
| | | | |
|
24 weeks treatment duration, n (%)
|
354 (37.3)
|
19 (54.3)
|
0.041
| | | | |
|
Baseline HCV-RNA, UI/ml, median [IQR]
|
995,500 [350,000–2,646,500]
|
729,000 [290,000–1,238,000]
|
0.123
| | | | |
|
Liver stiffness, kPa, median [IQR]
|
14.9 [11.8–22]
|
32 [18.5–44.4]
|
< 0.0001
|
1.048 [1.020–1.077]
|
0.001
|
1.057 [1.031–1.084]
|
0.000
|
|
SVR12, n (%)
|
933 (98.2)
|
33 (94.3)
|
0.09
| | | | |
|
DAA-SOF based, n (%)
|
707 (74.6)
|
31 (88.6)
|
0.09
| | | | |
|
DAA-RBV included, n (%)
|
690 (72.8)
|
15 (42.9)
|
< 0.0001
| | | | |
|
DAA-SOF + RBV, n (%)
|
562 (59.2)
|
12 (34.3)
|
0.003
| | | | |
|
DAA-SOF without RBV, n (%)
|
145 (20.5)
|
19 (61.3)
|
0.003
|
15.363 [6.668–35.396]
|
0.000
|
0.059 [0.025–0.137]
|
0.000
|
